THERAPEUTIC VALUE OF MEPITIOSTANE IN TREATMENT OF ADVANCED BREAST-CANCER

  • 1 January 1978
    • journal article
    • research article
    • Vol. 62  (5) , 743-745
Abstract
A new orally active antiestrogenic steroid, mepitiostane (20 mg/day), was given to 45 patients with advanced breast cancer. The regression rate was 31.1%, or 14 of 45 patients, and a duration of regression of > 6 mo. was obtained in 7 patients. Virilizing effects such as hoarseness, hirsutism and acne were observed relatively often but there was no evidence of abnormality in liver function tests or the serum Ca level.

This publication has 0 references indexed in Scilit: